Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Maiti · SciRah

Researcher profile · Semantic Scholar

A. Maiti

Share profile

A. Maiti — researcher profile on SciRah

h-index: 33
Works: 320
Citations: 4,221

Most-cited papers

Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia.
J. Senapati, Samuel Urrutia, S. Loghavi, N. Short +16 more
2023Blood61 citations
Semantic Scholar
Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML
G. Issa, Branko Cuglievan, N. Daver, C. Dinardo +24 more
2024Blood55 citations
Semantic Scholar
Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions
Kateryna Fedorov, A. Maiti, M. Konopleva
2023Cancers45 citations Open access
Semantic Scholar
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community
Branko Cuglievan, H. Kantarjian, J. Rubnitz, Todd M. Cooper +43 more
2024Leukemia33 citations Open access
Semantic Scholar
Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies
Adishwar Rao, Akriti Agrawal, G. Borthakur, V. Battula +1 more
2024Journal for ImmunoTherapy of Cancer32 citations Open access
Semantic Scholar
Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
M. Yilmaz, M. Muftuoglu, C. Dinardo, T. Kadia +20 more
2023Blood32 citations Open access
Semantic Scholar
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity
A. Bazinet, T. Kadia, N. Short, G. Borthakur +23 more
2023Blood Advances30 citations Open access
Semantic Scholar
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse
A. Bataller, H. Kantarjian, A. Bazinet, T. Kadia +19 more
2024Haematologica26 citations
Semantic Scholar
Oral decitabine/cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukemia: a phase 2 study
A. Bazinet, G. Garcia-Manero, N. Short, Y. Alvarado +21 more
2024The Lancet Haematology25 citations Open access
Semantic Scholar
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation
N. Short, F. Ong, F. Ravandi, Graciela M. Nogueras Gonzalez +16 more
2023Blood Advances24 citations Open access
Semantic Scholar
Disparate Leukemia Mutations Converge on Nuclear Phase-Separated Condensates
Gandhar K. Datar, Elmira Khabusheva, Archish Anand, Joshua Beale +21 more
2025Cell23 citations Open access
Semantic Scholar
First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics
A. Bajel, S. Garciaz, P. Desai, G. Huls +18 more
2023Blood23 citations Open access
Semantic Scholar
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups
A. Bataller, C. Dinardo, A. Bazinet, Naval G. Daver +14 more
2024American journal of hematology/oncology20 citations
Semantic Scholar
Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML
Wei-Ying Jen, C. Dinardo, N. Short, Aziz Farhat +20 more
2025Blood19 citations
Semantic Scholar
Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update
Himachandana Atluri, J. Mullin, Koichi Takahashi, S. Loghavi +20 more
2023Blood18 citations Open access
Semantic Scholar
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update
Jennifer Marvin-Peek, Jacqueline S. Garcia, G. Borthakur, G. Garcia-Manero +24 more
2024Blood16 citations
Semantic Scholar
Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
Daniel Nguyen, F. Ravandi, Sa A. Wang, J. Jorgensen +21 more
2024Blood14 citations
Semantic Scholar
A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
Daniel Nguyen, F. Ravandi, Sa A. Wang, J. Jorgensen +18 more
2023Blood12 citations Open access
Semantic Scholar
Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
Daniel Nguyen, H. Kantarjian, N. Short, N. Jain +12 more
2023Blood11 citations Open access
Semantic Scholar
A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).
N. Short, E. Jabbour, N. Jain, F. Haddad +14 more
2023Journal of Clinical Oncology11 citations
Semantic Scholar
Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
M. Yilmaz, M. Muftuoglu, N. Short, S. Loghavi +22 more
2024Blood9 citations
Semantic Scholar
A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure.
N. Short, Pavan Bachireddy, Xuelin Huang, H. Hwang +11 more
2023Journal of Clinical Oncology9 citations
Semantic Scholar
Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia.
K. Parmar, Rupayan Kundu, A. Maiti, S. Ball
2024Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis8 citations Open access
Semantic Scholar
Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse
Sankalp Arora, J. Senapati, S. Loghavi, P. Reville +22 more
2024Blood7 citations
Semantic Scholar
A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia
A. Bazinet, G. Garcia-Manero, N. Short, Y. Alvarado-Valero +18 more
2023Blood7 citations Open access
Semantic Scholar
γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction
S. Garciaz, P. Dumas, P. Peterlin, Daniel Morillo +14 more
2025Blood5 citations
Semantic Scholar
Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials
Jennifer Marvin-Peek, Himachandana Atluri, N. Short, A. Maiti +27 more
2024Blood5 citations Open access
Semantic Scholar
PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML
Kotoko Yamatani, Tatsuro Watanabe, Kaori Saito, Abdullah Khasawneh +11 more
2025Blood neoplasia4 citations Open access
Semantic Scholar
A Phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia
Sankalp Arora, H. Kantarjian, M. Maroun, G. Borthakur +11 more
2025Blood4 citations
Semantic Scholar
Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
J. Croden, D. Hammond, K. Chien, A. Maiti +10 more
2024Blood4 citations
Semantic Scholar
Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission
A. Bazinet, N. Daver, F. Ravandi, N. Short +18 more
2024Blood4 citations
Semantic Scholar
ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction
A. Maiti, P. Dumas, P. Peterlin, Daniel Morillo +11 more
2024Blood3 citations
Semantic Scholar
Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
Daniel Nguyen, H. Kantarjian, N. Short, Nitin Jain +13 more
2024Blood3 citations
Semantic Scholar
ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis
A. Maiti, N. Daver, William T. Johnson, Gaurav Goyal +16 more
2024Blood3 citations
Semantic Scholar
P494: A FIRST-IN-HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK-MYELODYSPLASIA
Anthony Selwyn Stein, M. Jongen-Lavrencic, S. Garciaz, G. Huls +15 more
2023HemaSphere3 citations Open access
Semantic Scholar
Targeting Myeloid Epithelial Tyrosine Kinase (MERTK) Receptor in Acute Myeloid Leukemia Using a Novel Antibody Drug Conjugate, Rgx-019-MMAE
Anudishi Tyagi, Maryam Siddiqui, Isabel Kurth, Shugaku Takeda +4 more
2023Blood3 citations Open access
Semantic Scholar
Cardio-safe degrader CT-03p degrades MCL-1 and overcomes venetoclax resistance in AML.
P. Mak, A. Maiti, T. Tomczyk, Sylvian Cottens +3 more
2025Blood2 citations
Semantic Scholar
Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes
Agata Gruszczynska, A. Maiti, Christopher A. Miller, S. M. Ramakrishnan +11 more
2024Haematologica2 citations Open access
Semantic Scholar
Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
A. Maiti, C. Dinardo, M. Ohanian, N. Daver +16 more
2023Blood2 citations Open access
Semantic Scholar
A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis
A. Maiti, N. Daver, S. Iyer, David McCall +10 more
2023Blood2 citations Open access
Semantic Scholar
Abstract CT101: Phase I study of the T-cell receptor-like antibody Hu8F4 in patients with advanced hematologic malignancies
T. Kadia, H. Kantarjian, G. Alatrash, Anna Sergeeva +19 more
2023Cancer Research2 citations
Semantic Scholar
Nuclear Phase Separation Drives NPM1-mutant Acute Myeloid Leukemia
Gandhar K. Datar, Elmira Khabusheva, Archish Anand, Joshua Beale +21 more
2025bioRxiv1 citations Open access
Semantic Scholar
Phase 1b study of HC-7366 alone and in combination with venetoclax and azacitidine in relapsed/refractory Acute Myeloid Leukemia
A. Maiti, S. Post, C. Dinardo, N. Daver +22 more
2025Blood1 citations
Semantic Scholar
Predictors of outcome in adult patients with Relapsed/Refractory T-cell acute lymphoblastic leukemia
Vanthana Bharathi, Nitin Jain, E. Jabbour, J. Senapati +7 more
2025Blood1 citations
Semantic Scholar
VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial
M. Swaminathan, C. Dinardo, A. Maiti, N. Pemmaraju +20 more
2025Blood Cancer Journal1 citations Open access
Semantic Scholar
Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia
Y. J. Kim, Ken Furudate, C. Dinardo, A. Maiti +37 more
2025Blood1 citations
Semantic Scholar
AML-804: Triplet Therapy With Decitabine, Venetoclax, and Quizartinib for FLT3-ITD Mutated AML: A Phase 1/2 Study
M. Yilmaz, M. Muftuoglu, N. Short, S. Loghavi +22 more
2025Clinical Lymphoma, Myeloma & Leukemia1 citations
Semantic Scholar
Dynamic biomarker trajectories predict outcomes in AML-associated hemophagocytic lymphohistiocytosis
Vaishali Gautam, B. Mescher, Rishab Prakash, I. Deshmukh +17 more
2025Blood1 citations
Semantic Scholar
Donor-Derived Variable Delta 2 (Vδ2) Gamma Delta (γδ) T Cells: A Promising Off-the-Shelf Therapeutic Strategy for Acute Myeloid Leukemia
Amanda Eckstrom, Adishwar Rao, Maryam Siddiqui, Anudishi Tyagi +4 more
2024Blood1 citations
Semantic Scholar
Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax
J. Croden, Jennifer Marvin-Peek, Marina Konopleva, G. Borthakur +22 more
2024Blood1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Short×33
Invite
N. Short — researcher profile on SciRah
F. Ravandi×33
Invite
F. Ravandi — researcher profile on SciRah
T. Kadia×30
Invite
T. Kadia — researcher profile on SciRah
C. Dinardo×30
Invite
C. Dinardo — researcher profile on SciRah

×28

Invite

N. Daver — researcher profile on SciRah

Invite

G. Issa — researcher profile on SciRah

G. Borthakur×23

Invite

G. Borthakur — researcher profile on SciRah

G. Garcia-Manero×23

Invite

G. Garcia-Manero — researcher profile on SciRah

H. Kantarjian×22

Invite

H. Kantarjian — researcher profile on SciRah

Invite

E. Jabbour — researcher profile on SciRah

Invite

M. Yilmaz — researcher profile on SciRah

G. Montalban-Bravo×18

Invite

G. Montalban-Bravo — researcher profile on SciRah